Arbor Wealth Management’s Moderna MRNA Stock Holding History

Arbor Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-64	Closed	-$1K	–	146
2019 Q2	$1K	Buy	+64	New	+$1.38K	﹤0.01%	204

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

RWA

Ropes Wealth Advisors Boston, Massachusetts $515M AUM 21.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arbor Wealth Management's MRNA Position: Q3 2019 in Review

Arbor Wealth Management sold out of Moderna (MRNA) in Q3 2019, closing a stake of 64 shares — an estimated $1K sold.

Arbor Wealth Management first reported a position in MRNA in Q2 2019 and held it in 1 quarter. The position peaked at $1K in Q2 2019. 136 funds tracked by Wall St. Rank hold MRNA as of Q3 2019.

Arbor Wealth Management reported no remaining Moderna position as of Q3 2019 after selling out during the quarter.
Arbor Wealth Management sold 64 Moderna shares in Q3 2019, an estimated $1K.
Arbor Wealth Management first reported a position in Moderna in Q2 2019 and held it in 1 quarter.
Arbor Wealth Management's Moderna position peaked at $1K in Q2 2019.
136 funds tracked by Wall St. Rank held Moderna as of Q3 2019.

Based on Arbor Wealth Management's 13F filing for Q3 2019, filed 6 Nov 2019.